大梗死核心血管内治疗的临床严重程度与结局:ANGEL-ASPECT试验的事后分析
该研究为ANGEL-ASPECT随机对照试验的事后分析,纳入中国46个中心455例前循环大血管闭塞所致大梗死核心患者,按基线NIHSS评分<20或≥20分为中度与重度卒中。中度卒中患者接受EVT较单纯药物治疗90天mRS分布显著改善(广义比值比1.66,95%CI 1.29-2.13,P<0.001),重度卒中无显著差异(广义比值比1.06,95%CI 0.54-2.10,P=0.87),交互作用P=0.03。
要点
- 中度卒中(NIHSS<20)患者EVT组90天mRS分布优于单纯药物治疗组(广义比值比1.66,95%CI 1.29-2.13,P<0.001)。
- 重度卒中(NIHSS≥20)患者EVT组与单纯药物治疗组90天mRS无显著差异(广义比值比1.06,95%CI 0.54-2.10,P=0.87)。
- 卒中严重程度与治疗效应存在显著交互作用(P=0.03),选择大梗死核心患者行EVT时应考虑卒中严重程度。
核心结论
- 在急性大梗死核心患者中,中度卒中患者接受EVT与单纯药物治疗相比功能结局改善,重度卒中患者未见显著差异。
- 因此,在选择大梗死核心患者进行EVT时,应考虑卒中严重程度。
研究设计与样本
- 本研究为ANGEL-ASPECT试验的事后分析,该试验为随机对照试验,于2020年10月2日至2022年5月18日在中国46个中心纳入患者。
- 纳入标准为前循环大血管闭塞所致大梗死核心(Alberta卒中项目早期CT评分3-5分或梗死核心体积70-100 mL),发病24小时内,NIHSS评分6-30分。
- 患者随机分为EVT组或单纯药物治疗(MM)组;本分析按基线NIHSS评分<20或≥20分为中度卒中与重度卒中两个亚组。
- 共纳入455例符合条件患者,其中中度卒中347例(76.3%;EVT组170例,MM组177例),重度卒中108例(23.7%;EVT组60例,MM组48例)。
主要发现
- 中度卒中患者中,EVT组较MM组90天mRS分布显著改善(广义比值比1.66,95%CI 1.29-2.13;P<0.001)。
- 重度卒中患者中,EVT组与MM组90天mRS分布无显著差异(广义比值比1.06,95%CI 0.54-2.10;P=0.87)。
- 卒中严重程度与治疗效应存在显著交互作用(P=0.03)。
关键数值与推荐
- 大梗死核心定义为Alberta卒中项目早期CT评分3-5分或梗死核心体积70-100 mL。
- 中度卒中定义为基线NIHSS评分<20分,重度卒中定义为基线NIHSS评分≥20分。
- 主要结局为90天改良Rankin量表序贯评分(0分无症状至6分死亡)。
临床怎么用
- 作者认为,在选择大梗死核心患者进行EVT时,应考虑卒中严重程度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular therapy (EVT) has been proven effective for patients with acute ischemic stroke with large infarcts. This study aimed to explore the impact of clinical severity on the efficacy of EVT in such patients. METHODS: This was a post hoc analysis of the ANGEL-ASPECT trial (Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core), a randomized controlled trial that enrolled patients from 46 centers across China between October 2, 2020, and May 18, 2022. These patients had large infarcts (defined as Alberta Stroke Program Early CT Score of 3-5 or infarct-core volume 70-100 mL) due to anterior-circulation large vessel occlusion within 24 hours after stroke onset with a National Institutes of Health Stroke Scale score of 6 to 30. Patients were randomized into either the EVT group or the medical management alone (MM) group. For this analysis, we categorized the patients into 2 subgroups: moderate stroke and severe stroke, based on a baseline National Institutes of Health Stroke Scale score of either <20 or ≥20. The primary outcome was the ordinal 90-day modified Rankin Scale score (0, no symptoms, to 6, death). RESULTS: Among 455 eligible patients, 347 (76.3%) presented with moderate stroke (170 received EVT, 177 underwent MM), and 108 (23.7%) had severe stroke (60 received EVT, 48 underwent MM). A significant shift toward better outcomes in the 90-day modified Rankin Scale distribution was observed in the EVT group compared with the MM group (generalized odds ratio, 1.66 [95% CI, 1.29-2.13]; P<0.001) among patients with moderate stroke. However, this was not the case for those with severe stroke (generalized odds ratio, 1.06 [95% CI, 0.54-2.10]; P=0.87), indicating a significant interaction (P=0.03). CONCLUSIONS: In patients with acute large infarcts, EVT was associated with improved functional outcomes compared with MM in patients with moderate stroke. However, no significant difference was observed in patients with severe stroke. Therefore, stroke severity should be considered when selecting patients with large infarcts for EVT. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04551664.
引用
- Lu Q, Zheng L, Nie X, et al. Clinical Severity and Outcomes in Large Infarcts With Endovascular Therapy: A Post Hoc Analysis of the ANGEL-ASPECT Trial. Stroke. 2025. PMID: 40013350. doi:10.1161/STROKEAHA.124.049315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。